Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow, S. Forster, Y. Winter, J.P. Bach, J. Popp, J. Alferink, J. Wiltfang, K Buerger, M. Otto, P. Antuono, M. Jacoby, R. Richter, J. Stevens, I. Melamed, J. Goldstein, S. Haag & 3 others S. Wietek, M. Farlow, F. Jessen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)233-243
JournalLancet Neurology
Volume12
Issue number3
DOIs
Publication statusPublished - 2013

Cite this

Dodel, R. ; Rominger, A. ; Bartenstein, P. ; Barkhof, F. ; Blennow, K. ; Forster, S. ; Winter, Y. ; Bach, J.P. ; Popp, J. ; Alferink, J. ; Wiltfang, J. ; Buerger, K ; Otto, M. ; Antuono, P. ; Jacoby, M. ; Richter, R. ; Stevens, J. ; Melamed, I. ; Goldstein, J. ; Haag, S. ; Wietek, S. ; Farlow, M. ; Jessen, F. / Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. In: Lancet Neurology. 2013 ; Vol. 12, No. 3. pp. 233-243.
@article{baa4285922394b5884af94323066d666,
title = "Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial",
author = "R. Dodel and A. Rominger and P. Bartenstein and F. Barkhof and K. Blennow and S. Forster and Y. Winter and J.P. Bach and J. Popp and J. Alferink and J. Wiltfang and K Buerger and M. Otto and P. Antuono and M. Jacoby and R. Richter and J. Stevens and I. Melamed and J. Goldstein and S. Haag and S. Wietek and M. Farlow and F. Jessen",
year = "2013",
doi = "10.1016/S1474-4422(13)70014-0",
language = "Undefined/Unknown",
volume = "12",
pages = "233--243",
journal = "Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "3",

}

Dodel, R, Rominger, A, Bartenstein, P, Barkhof, F, Blennow, K, Forster, S, Winter, Y, Bach, JP, Popp, J, Alferink, J, Wiltfang, J, Buerger, K, Otto, M, Antuono, P, Jacoby, M, Richter, R, Stevens, J, Melamed, I, Goldstein, J, Haag, S, Wietek, S, Farlow, M & Jessen, F 2013, 'Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial' Lancet Neurology, vol. 12, no. 3, pp. 233-243. https://doi.org/10.1016/S1474-4422(13)70014-0

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. / Dodel, R.; Rominger, A.; Bartenstein, P.; Barkhof, F.; Blennow, K.; Forster, S.; Winter, Y.; Bach, J.P.; Popp, J.; Alferink, J.; Wiltfang, J.; Buerger, K; Otto, M.; Antuono, P.; Jacoby, M.; Richter, R.; Stevens, J.; Melamed, I.; Goldstein, J.; Haag, S.; Wietek, S.; Farlow, M.; Jessen, F.

In: Lancet Neurology, Vol. 12, No. 3, 2013, p. 233-243.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

AU - Dodel, R.

AU - Rominger, A.

AU - Bartenstein, P.

AU - Barkhof, F.

AU - Blennow, K.

AU - Forster, S.

AU - Winter, Y.

AU - Bach, J.P.

AU - Popp, J.

AU - Alferink, J.

AU - Wiltfang, J.

AU - Buerger, K

AU - Otto, M.

AU - Antuono, P.

AU - Jacoby, M.

AU - Richter, R.

AU - Stevens, J.

AU - Melamed, I.

AU - Goldstein, J.

AU - Haag, S.

AU - Wietek, S.

AU - Farlow, M.

AU - Jessen, F.

PY - 2013

Y1 - 2013

U2 - 10.1016/S1474-4422(13)70014-0

DO - 10.1016/S1474-4422(13)70014-0

M3 - Article

VL - 12

SP - 233

EP - 243

JO - Lancet Neurology

JF - Lancet Neurology

SN - 1474-4422

IS - 3

ER -